Thrombotic diseases, in particular cardiovascular and cerebrovascular thrombotic diseases, have become the top cause of death in the population of China, and their incidence has increased, seriously endangering human health.

China has been engaged in the R&D and manufacturing of semi-automatic coagulation analyzers for over a decade, and based on the data from the website of the NMPA, in 2024 and 2025 (as od 15 August), a total of 2 instruments from 2 manufacturers have obtained registration certificates...

On July 27, Illumina and KingMed Diagnostics Group Co., Ltd. reached a new strategic cooperation on tumor gene detection.

Hologic reported after the close of the market on Wednesday that declining sales of COVID-19 assays and difficulties obtaining semiconductor chips contributed to an overall 14 percent year-over-year decline in its fiscal third quarter revenues.

BioGX said on Wednesday that it has obtained CE-IVD marking for a point-of-care, multiplex RT-PCR SARS-CoV-2 assay.

On July 28, Innovita Biological Technology Co., Ltd. was listed on the SSE STAR Market with the stock code of 688253. Its issue price was CNY 26.06 per share. After the opening, the market value exceeded CNY 4.6 billion.

AstraZeneca's acquisition of TeneoTwo will give the company access to its clinical-stage T-cell engager, TNB-486, strengthening their hematological cancer pipeline.

Roche’s new test is the first available immunoassay that allows for simultaneous, independent determination of the hepatitis C virus antigen and antibody status.

On July 26, 2022, China Securities Regulatory Commission approved MGI’s IPO registration on the sci-tech innovation board.

3M (NYSE: MMM) today announced its intent to spin off its Health Care business, resulting in two world-class public companies well positioned to pursue their respective growth plans.

DiaSorin said Friday it received 501(k) clearance from the US Food and Drug Administration to market its Liaison MeMed BV, a high-throughput immune-response assay that can differentiate between bacterial and viral infections.

Qiagen on Tuesday afternoon reported strong year-over-year sales growth in its core non-COVID-related product portfolio, prompting the company to raise its full-year revenue and earnings guidance even as its COVID-19-related business remains volatile.